Novo-Nordisk is a healthcare company. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. The diabetes and obesity care segment covers insulin, GLP-1 and related delivery systems, oral antidiabetic products, obesity and other diseases. The biopharm segment covers the therapy areas of haemophilia, growth disorders and hormone replacement therapy. Co.'s products include NovoLog®/ NovoRapid®, NovoLog Mix®/ NovoMix®, Levemir®, Victoza®, Tresiba®, Ryzodeg®, Xultophy®, Fiasp®, Ozempic®, Saxenda®, Rybelsus® , NovoSeven®, NovoEight®, Rebinyn®/ Refixia®, Norditropin®, Esperoct® and devices.